SOURCE: biOasis Technologies Inc.

biOasis Technologies Inc.

November 10, 2015 17:00 ET

biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies -- Inclusive of Trastuzumab -- to Treat Her2/neu Brain Metastases

VANCOUVER, BC--(Marketwired - November 10, 2015) -

  • biOasis' Transcend Platform has shown great utility in pre-clinical animal models to deliver therapeutic compounds into the brain at sufficient levels to reach a therapeutic effect. Without the Transcend delivery vehicle these compounds would otherwise be excluded from the brain due to the presence of the protective blood-brain barrier.
  • The issuance of this patent indicates that compounds, such as in this case Trastuzumab can be, with the help of Transcend, protected under the issuance of a new patent, including for a new therapeutic indication -- brain metastases. Trastuzumab coupled to the transport vector Transcend thus offers a potential treatment for this dreadful cancer.

BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the full and final issuance of a US patent covering the delivery by Transcend of cancer therapeutics to the brain to treat an aggressive form of brain cancer -- Her2+/nue brain metastases.

Her2+ brain cancer is a form of an aggressive breast cancer that travels (metastasizes) to the brain at a high frequency. In 2012 it was noted that upwards of 20% of Her2+ breast cancer patients exhibited brain metastases. Today, the incidence has been reported to be as high as 40%*. Arguably this is due to the tremendous job achieved by the primary drug used to treat this form of cancer, Trastuzumab (brand name Herceptin©). Since its introduction as a therapeutic treatment, Trastuzamab has increased survival significantly, but as a result there is a higher incidence of Her2/neu brain metastases. This drug alone does not readily cross the blood-brain barrier and, as such, the treatment of metastatic brain cancer presents a significant challenge to physicians. biOasis, in collaboration with a number of independent third parties, including Texas Tech University, the National Research Council of Canada and the BC Cancer Research Centre, has shown some highly promising results using biOasis' combination of Trastuzumab with its Transcend delivery platform to deliver the therapeutic to the brain.

"We filed this patent in 2012 when we first obtained our positive results with the Trastuzamab-Transcend combination and to have the patent fully granted by 2015 is a wonderful example of the tremendous opportunity for the Transcend family as a whole," said Rob Hutchison CEO, "and it shows that the marriage of our Transcend platform with an on or off patent therapeutic can obtain patent protection for our shareholders. But much more importantly, this may one day offer a treatment for those patients who may see brain involvement of this dreaded disease even after beating the primary site location. This patent greatly enhances biOasis' intellectual property position and along with collaborators, such as the Harvard research team at Brigham & Women's Hospital, enables us to advance in earnest our MTfp-TZM program with the ultimate goal to have a therapeutic protocol for Her2/neu brain metastases."

* http://www.nature.com/nrc/journal/v5/n8/full/nrc1670.html

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Richmond, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Contact Information

  • Company Contact
    General: 778-383-3280 #101
    biOasis Technologies Inc.
    info@bioasis.ca